

LISTING OF THE CLAIMS

 X This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims:

1. (Currently Amended) A use of one or more steroids conjugated with one or more mammalian proteins for the manufacture of a pharmaceutical composition for the treatment or diagnosis of solid cancers or hematological malignancies, wherein the steroid is not a cytostaticum.
2. (Currently Amended) The use according to claim 1, wherein the steroid is selected among from the group consisting of: testosterone, estrogen, estradiol, progesterone, cortisol, glucocorticoids ~~or~~ and any known analogs thereof.
3. (Currently Amended) The use according to claim 1 ~~or 2~~, wherein the mammalian proteins are selected among from the group consisting of globular proteins, plasma proteins, albumins, binders ~~or~~ and antibodies of selective human tumoral cell antigens.
4. (Currently Amended) The use according to claim 3, wherein the mammalian protein is human albumin or bovine serum albumin.
5. (Currently Amended) The use according to ~~any of the claims 1-4~~ claim 1, wherein the pharmaceutical composition further comprises a cytoskeleton acting drug.
6. (Currently Amended) The use according to claim 5, wherein the cytoskeleton acting drug is Taxol® or Taxotere®.

7. (Currently Amended) The use according to ~~any of the claims 1-6~~ claim 1, wherein the pharmaceutical composition further comprises one of an antiandrogen, an antiestrogen and an antiprogestin in case that the tumor to be treated or diagnosed is bearing testosterone-, estrogen- or progesterone- receptors, respectively.
8. (Currently Amended) The use according to claim 7, wherein the antiandrogen is cyproterone acetate or flutamide.
9. (Currently Amended) The use according to claim 7, wherein the antiestrogen is tamoxifene.
10. (Currently Amended) The use according to claim 7, wherein the antiprogesterone is RU486.
11. (Currently Amended) The use according to ~~any of the claims 1-10~~ claim 1, wherein the solid cancer is selected ~~among~~ from the group consisting of: prostate adenocarcinoma (hormone sensitive or resistant) and its metastases, breast cancer and its metastases in any places, pheochromocytomas and their metastases, bone tumor and their metastases and brain tumor (~~neurobrastomas~~ neuroblastomas).
12. (Currently Amended) The use according to ~~any of the claims 1-10~~ claim 1, wherein the haematological malignancies are selected ~~among~~ from the group consisting of acute and chronic myeloid leukaemia, acute and chronic lymphoid leukaemia and lymphomas (B and T).
13. (Currently Amended) A pharmaceutical composition comprising one or more steroids, which are not cytostaticum, conjugated with mammalian proteins and a cytoskeleton-acting drug.

14. (Currently Amended) The pharmaceutical composition according to ~~claim 2~~ claim 13, wherein the steroid is selected ~~among~~ from the group consisting of: testosterone, estrogen, estradiol, progesterone, cortisol, glucocorticoids ~~or~~ and any known analogs thereof.
15. (Currently Amended) The pharmaceutical composition according to claim 13 ~~or 14~~, wherein the mammalian proteins are selected ~~among~~ from the group consisting of globular proteins, plasma proteins, albumins, binders ~~or~~ and antibodies of selective human tumoral cell antigens.
16. (Currently Amended) The pharmaceutical composition according to claim 15, wherein the mammalian protein is human albumin or bovine serum albumin.
17. (Currently Amended) The pharmaceutical composition according to ~~any of the claims 13 to 16~~ claim 13, wherein the cytoskeleton acting drug is Taxol® or Taxotere®.
18. (Currently Amended) The pharmaceutical ~~composiotion~~ composition according to ~~any of the claims 13 to 17~~ claim 13, which further comprises an antiandrogen, an antiestrogen and an antiprogesterone in case that the tumor to be treated or diagnosed is bearing testosterone-, estrogen- or progesterone- receptors, respectively.
19. (Currently Amended) A use of a pharmaceutical composition according to ~~any of the claims 13-18~~ claim 13, ~~or a pharmaceutical composition prepared according to any of the claims 1-12~~, for the treatment of solid cancer or haematological malignancies.
20. (Currently Amended) The use according to claim 19, wherein the solid cancer is selected ~~among~~ from the group consisting of: prostate adenocarcinoma (hormone sensitive or resistant) and its metastases, breast cancer and its metastases in any places, pheochromocytomas and their metastases, bone tumor and their metastases and brain tumor (~~neurobrastomas~~ neuroblastomas).

21. (Currently Amended) The use according to claim 19, wherein the haematological malignancies are selected ~~among~~ from the group consisting of: acute and chronic myeloid leukaemia, acute and chronic lymphoid leukaemia and lymphomas (B and T).
22. (Currently Amended) A diagnostic method for the detection of solid cancer or haematological disorders, comprising the following steps:
- i) contacting the specimens with a solution ~~of a pharmaceutical composition comprising a steroid conjugate wherein the steroid is conjugated with one or more mammalian proteins for the manufacture of a pharmaceutical composition for the treatment or diagnosis of solid cancers or hematological malignancies, wherein the steroid is not a cytostaticum according to claim 1;~~
 - ii) detecting the amount of conjugate of ~~steriod~~ steroid conjugated to mammalian protein is bound to the specimen; and
 - iii) based on the reading in ii) determining if the specimens contains tissue inflicted with solid cancer or a haematological disorder.
23. (Currently Amended) The method according to claim 22, wherein the conjugate further comprise a labelling.
24. (Currently Amended) A kit comprising:
a pharmaceutical composition comprising one or more steroids, which are not cytostaticum, conjugated with a mammalian protein; and
a pharmaceutical composition comprising a cytoskeleton acting drug, or one of an antiandrogen, an antiestrogen and an antiprogesterin in case that the tumor is bearing testosterone-, estrogen- or progesterone- receptors, respectively.
25. (Currently Amended) The kit according to claim 24, comprising:

a pharmaceutical composition comprising one or more steroids, which are not
cytostaticum, conjugated with a mammalian protein; and
a pharmaceutical composition comprising a cytoskeleton acting drug, and
one of an antiandrogen, an antiestrogen and an antiprogesterin in case that the tumor is
bearing testosterone-, estrogen- or progesterone- receptors, respectively.

26. (New) The use according to claim 2, wherein the mammalian proteins are selected from the group consisting of globular proteins, plasma proteins, albumins, binders or antibodies of selective human tumoral cell antigens.
27. (New) The pharmaceutical composition according to claim 14, wherein the mammalian proteins are selected from the group consisting of globular proteins, plasma proteins, albumins, binders or antibodies of selective human tumoral cell antigens.